Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions

Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing healthcare problem with limited therapeutic options. Progress in this field depends on the availability of reliable preclinical models. Human precision-cut liver slices (PCLSs) have been employed to replicate the initiatio...

Full description

Bibliographic Details
Main Authors:	Mei Li, Frederik T. Larsen, Marius C. van den Heuvel, Konstanze Gier, Alan R. Gorter, Dorenda Oosterhuis, Johan Bijzet, Vincent E. de Meijer, Kim Ravnskjaer, Anika Nagelkerke, Peter Olinga
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Nutrients
Subjects:	precision-cut liver slices (PCLSs) long-term incubation metabolic dysfunction-associated steatotic liver disease (MASLD) non-alcoholic fatty liver disease (NAFLD) hepatic steatosis liver fibrosis
Online Access:	https://www.mdpi.com/2072-6643/16/5/626

Similar Items

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
by: Gary Huang, et al.
Published: (2023-10-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
by: Guillaume Henin, et al.
Published: (2024-02-01)

Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Erika Choi, et al.
Published: (2024-02-01)

Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease
by: Georg Semmler, et al.
Published: (2023-09-01)

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
by: Jingli Gao, et al.
Published: (2024-03-01)

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Avneet Singh, et al.
Published: (2024-02-01)

Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Amani Al-Shargi, et al.
Published: (2023-11-01)

Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study
by: Michihiro Iwaki, et al.
Published: (2024-04-01)

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
by: Joo Hyun Oh, et al.
Published: (2024-04-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
by: Ana Sandoval-Rodriguez, et al.
Published: (2024-02-01)

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
by: Baoqiang Zhu, et al.
Published: (2023-11-01)

Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population
by: Andrea Dalbeni, et al.
Published: (2023-10-01)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
by: Koki Nagai, et al.
Published: (2023-10-01)

Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD
by: Daniela Gabbia, et al.
Published: (2023-11-01)

Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review
by: Miren García-Cortés, et al.
Published: (2023-12-01)

New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score
by: Lei Peng, et al.
Published: (2024-01-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease
by: Tiansu Lv, et al.
Published: (2024-02-01)

Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements
by: Mislav Barisic-Jaman, et al.
Published: (2024-01-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

The Role of Neuregulin-1 in Steatotic and Non-Steatotic Liver Transplantation from Brain-Dead Donors
by: Marc Micó-Carnero, et al.
Published: (2022-04-01)

Steatotic liver disease among lean and non-lean individuals in Southern Lao PDR: a cross-sectional study of risk factors
by: Anousin Homsana, et al.
Published: (2024-12-01)

Role of Dietary Nutritional Treatment on Hepatic and Intestinal Damage in Transplantation with Steatotic and Non-Steatotic Liver Grafts from Brain Dead Donors
by: Marc Micó-Carnero, et al.
Published: (2021-07-01)

Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study
by: Mauricio Gabrielli, et al.
Published: (2012-11-01)

Iron, Oxidative Stress, and Metabolic Dysfunction—Associated Steatotic Liver Disease
by: Sophie Gensluckner, et al.
Published: (2024-02-01)

A Novel Oxygen Carrier (M101) Attenuates Ischemia-Reperfusion Injuries during Static Cold Storage in Steatotic Livers
by: Njikem Asong-Fontem, et al.
Published: (2021-08-01)

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside
by: Pojsakorn Danpanichkul, et al.
Published: (2024-01-01)

An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Xiongcai Feng, et al.
Published: (2023-11-01)

Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases
by: Madan Kumar Arumugam, et al.
Published: (2023-10-01)

NO–IL-6/10–IL-1β axis: a new pathway in steatotic and non-steatotic liver grafts from brain-dead donor rats
by: Araní Casillas-Ramírez, et al.
Published: (2023-08-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)

Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Raquel Benedé-Ubieto, et al.
Published: (2024-12-01)

Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression
by: Julius W. Jaeger, et al.
Published: (2024-03-01)

The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease
by: Jaejun Lee, et al.
Published: (2024-02-01)

Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD
by: Bianca Heller, et al.
Published: (2023-09-01)

Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
by: Luciana Agoglia, et al.
Published: (2024-07-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
by: Wayne Eskridge, et al.
Published: (2023-09-01)

Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Shuangshuang Zhao, et al.
Published: (2024-01-01)

Modeling Nonalcoholic Fatty Liver Disease in the Dish Using Human-Specific Platforms: Strategies and LimitationsSummary
by: Milad Rezvani, et al.
Published: (2023-01-01)